TORO Clinical Trials

Achieved all primary and secondary endpoints

Substantial improvement in immune status

Fuzeon did not add to toxicities of background drugs

Injection site reactions were the most common AE, but limiting in only 3%

Previous slide Next slide Back to first slide View graphic version